Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Corticotropin-releasing factor 1 (CRF(1)) receptor antagonists may represent a novel group of drugs for the pharmacotherapy of depression and/or anxiety disorders. We have investigated the behavioral, endocrine, and neurochemical effects of chronic administration of a selective CRF(1) receptor antagonist, CP-154,526. After 9 to 10 days of treatment with CP-154,526 (3.2 mg/kg/day), defensive withdrawal behavior was significantly decreased suggesting anxiolytic activity. In animals treated for 14 days with the low dose of CP-154,526, serum corticosterone concentrations returned to baseline levels faster after application of an airpuff startle. Using in situ hybridization, no changes in CRF(1) receptor mRNA expression were detected in parietal cortex, basolateral amygdala, or cerebellum after chronic treatment with CP-154,526. A dose-dependent decrease in CRF mRNA expression was observed in the hypothalamic paraventricular nucleus (PVN) and the Barrington's nucleus, an effect that was significant at the high but not the low dose of CP-154,526. CP-154,526 did not alter central CRF(2A) receptor binding or mRNA expression, or urocortin mRNA expression. The present findings suggest that chronic administration of CP-154, 526 produces anxiolytic-like effects but no evidence of adrenal insufficiency. Previous postmortem studies revealed increased CRF peptide and mRNA levels in the PVN of depressed patients, which may mediate the hyperactivity of the hypothalamic-pituitary-adrenal axis observed in such patients. In view of a possible use for CRF(1) receptor antagonists in the treatment of depression, the present finding that CP-154,526 decreases CRF synthesis in the PVN is of considerable interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Self-citationTimpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919 · cited 1×
“Studies using CRF1 receptor knockout mice and CRF1 and CRF2 receptor antisense oligonucleotides have revealed that the anxiogenic effect of CRF appears to be mediated by the CRF1 receptor subtype (Heinrichs et al., 1997; Smith et al., 1998; Timpl et al., 1998).”
BackgroundSmith, G. W., Aubry, J.-M., Dellu, F., Contarino, A., Bilezikjian, L. M., Gold, L. H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C. A., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80491-2 · Cited by 892
PSYCHONEUROENDOCRINOLOGY OF DEPRESSION
Plotsky, P. M., Owens, M. J., & Nemeroff, C. B. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70006-x · Cited by 672 · cited 1×
“After antidepressant treatment, measures of hyperactivity HPA axis and CRF function appear to normalize suggesting that hyperactivity of CRF neurons is a state marker for depression (Plotsky et al., 1998; Holsboer, 1999).”
Self-citationRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
Butler, P., Weiss, J., Stout, J., & Nemeroff, C. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-01-00176.1990 · Cited by 402
Deak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier, S. F., Licinio, J., Wong, M.-L., Chrousos, G. P., Webster, E., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6415 · Cited by 242
Liebsch, G., Landgraf, R., Gerstberger, R., Probst, J. C., Wotjak, C. T., Engelmann, M., Holsboer, F., & Montkowski, A. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00099-w · Cited by 220 · cited 1×
“Thus, it is reasonable to believe that approximately the same degree of CRF1 receptor blockade occurs in other brain regions, i.e., the amygdala which appears to mediate the anxiolytic effects of CRF1 receptor antagonists (Swiergiel et al., 1993; Liebsch et al., 1995, 1999).”
BackgroundAntidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
Mansbach, R. S., Brooks, E. N., & Chen, Y. L. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00025-3 · Cited by 195 · cited 1×
“Moreover, CP-154,526 exhibits antidepressant-like activity in the learned helplessness paradigm (Mansbach et al., 1997).”
Background
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Neuroendocrine pharmacology of stress
Carrasco, G. A., & Van de Kar, L. D. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01285-8 · Cited by 914
“All the antagonist of the CRF1 receptor inhibit the ACTH/corticosterone response to stressors and have a good anxiolytic score (Arborelius et al., 2000; Gully et al., 2002; Habib et al., 2001; Kim et al., 1998; Maciag et al., 2002; Pelleymounter et al., 2002).”
BackgroundRole of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
van Praag, H. M. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.031 · Cited by 377
Makino, S., Hashimoto, K., & Gold, P. W. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00791-8 · Cited by 260
Metadata
- Authors
- Arborelius, L., Skelton, K. H., Thrivikraman, K. V., Plotsky, P. M., Schulz, D. W., & Owens, M. J.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2000-08
- Volume
- 294
- Issue
- 2
- Pages
- 588-597
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2182477917
- Cited by
- 101
- References
- 9
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat. https://app.cochat.ai/papers/10.1016/s0022-3565(24)39110-4
- The paper
- Arborelius, L., Skelton, K. H., Thrivikraman, K. V., Plotsky, P. M., Schulz, D. W., & Owens, M. J. (2000). Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)39110-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.